An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy

Trial Profile

An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Feb 2019.
    • 31 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Feb 2019.
    • 23 Jun 2017 This trial has been completed in Finland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top